Compare Stocks

→ Move Your Money Before May 22 (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$5.41 +5.0%	$5.61	$2.68 ▼ $8.22	$170.42M	3.99	303,119 shs	632,424 shs
LUMO Lumos Pharma	$2.77 +0.4%	$2.83	$2.41 ▼ $4.55	$22.49M	0.65	20,312 shs	688 shs
OTIC Otonomy	$0.01	$0.06	$0.01 ▼ $2.54	$582K	1.54	937,525 shs	N/A
SMMT Summit Therapeutics	$3.86 +8.7%	$4.08	$1.30 ▼ $5.22	$2.71B	-1.21	2.17 million shs	1.39 million shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+2.18%	+1.98%	-18.38%	+27.16%	+30.38%
LUMO Lumos Pharma	-2.13%	+5.34%	-3.50%	-4.00%	-12.10%
OTIC Otonomy	0.00%	0.00%	0.00%	0.00%	0.00%
SMMT Summit Therapeutics	-1.11%	+1.14%	-5.08%	-8.51%	+161.99%

Move Your Money Before May 1 (Ad)

Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens?

Click here to get the full story before May 1.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPR Capricor Therapeutics	1.1091 of 5 stars	3.5	0.0	0.0	0.0	2.4	0.8	0.6
LUMO Lumos Pharma	1.5791 of 5 stars	3.5	1.0	0.0	0.0	0.0	2.5	1.3
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	1.3255 of 5 stars	3.5	0.0	0.0	0.0	1.8	3.3	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	3.00	Buy	$24.00	343.62% Upside
LUMO Lumos Pharma	3.00	Buy	$18.00	549.82% Upside
OTIC Otonomy	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	3.00	Buy	$8.00	107.25% Upside

Current Analyst Ratings

Latest SMMT, LUMO, OTIC, and CAPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/25/2024	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
3/26/2024	SMMT Summit Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
3/20/2024	LUMO Lumos Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
3/1/2024	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$25.18M	6.77	N/A	N/A	$0.73 per share	7.41
LUMO Lumos Pharma	$2.05M	10.97	N/A	N/A	$3.45 per share	0.80
OTIC Otonomy	$130K	4.48	N/A	N/A	$0.97 per share	0.01
SMMT Summit Therapeutics	$700K	3,869.37	N/A	N/A	$0.11 per share	35.09

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$22.29M	-$0.87	N/A	45.08	N/A	-88.52%	-299.67%	-45.54%	5/9/2024 (Estimated)
LUMO Lumos Pharma	-$34.03M	-$4.19	N/A	N/A	N/A	-1,659.39%	-85.63%	-65.30%	5/1/2024 (Estimated)
OTIC Otonomy	-$51.18M	-$0.77	N/A	∞	N/A	N/A	-137.86%	-68.50%	N/A
SMMT Summit Therapeutics	-$614.93M	-$1.53	N/A	N/A	N/A	N/A	-87.45%	-41.17%	5/1/2024 (Confirmed)

Latest SMMT, LUMO, OTIC, and CAPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2024	N/A	SMMT Summit Therapeutics	-$0.06	N/A	+$0.06	N/A	N/A	N/A
3/7/2024	Q4 2023	LUMO Lumos Pharma	-$1.18	-$1.17	+$0.01	-$1.17	$0.01 million	$0.83 million
2/29/2024	Q4 2023	CAPR Capricor Therapeutics	-$0.23	-$0.02	+$0.21	-$0.02	$5.80 million	$12.09 million
2/20/2024	Q4 2023	SMMT Summit Therapeutics	N/A	-$0.05	-$0.05	-$0.05	N/A	$0.20 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
LUMO Lumos Pharma	N/A	N/A	N/A	N/A	N/A
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	1.63	1.63
LUMO Lumos Pharma	N/A	5.69	5.69
OTIC Otonomy	N/A	1.74	1.74
SMMT Summit Therapeutics	1.29	9.30	9.30

Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
LUMO Lumos Pharma	33.99%
OTIC Otonomy	41.23%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	12.00%
LUMO Lumos Pharma	25.40%
OTIC Otonomy	1.09%
SMMT Summit Therapeutics	83.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	N/A	31.50 million	27.72 million	Optionable
LUMO Lumos Pharma	33	8.12 million	6.06 million	Not Optionable
OTIC Otonomy	51	68.53 million	67.78 million	Optionable
SMMT Summit Therapeutics	105	701.70 million	114.38 million	Optionable

SMMT, LUMO, OTIC, and CAPR Headlines

Source	Headline
	Summit Therapeutics (SMMT) Scheduled to Post Quarterly Earnings on Wednesday marketbeat.com - April 25 at 11:45 AM
	Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 businesswire.com - April 24 at 4:30 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Up 10.6% marketbeat.com - April 23 at 3:43 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Crosses Below Fifty Day Moving Average of $4.14 americanbankingnews.com - April 23 at 5:34 AM
	Short Interest in Summit Therapeutics Inc. (NASDAQ:SMMT) Grows By 28.6% marketbeat.com - April 13 at 7:47 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.7% marketbeat.com - April 12 at 3:59 PM
	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors finance.yahoo.com - April 11 at 5:11 PM
	Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors businesswire.com - April 11 at 4:30 PM
	Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum businesswire.com - April 10 at 7:00 AM
	Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor reuters.com - April 9 at 4:33 PM
	Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer prnewswire.com - April 9 at 4:05 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down to $3.95 marketbeat.com - April 4 at 2:02 PM
	Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6% marketbeat.com - April 1 at 4:50 PM
	Summit Therapeutics CEO acquires shares worth over $411k investing.com - March 29 at 8:13 PM
	Why Summit Therapeutics Stock Crushed the Market This Week fool.com - March 29 at 5:43 PM
	Insider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Acquires 30,000 Shares of Stock insidertrades.com - March 29 at 7:14 AM
	Summit Therapeutics (NASDAQ:SMMT) Trading 18.9% Higher After Insider Buying Activity marketbeat.com - March 28 at 10:31 AM
	Insider Buying: Summit Therapeutics Inc. (NASDAQ:SMMT) CEO Buys 30,000 Shares of Stock marketbeat.com - March 27 at 9:29 PM
	Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $3.28 marketbeat.com - March 26 at 12:25 PM
	Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024 businesswire.com - March 14 at 7:00 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT prnewswire.com - March 11 at 6:05 PM
	Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT accesswire.com - March 6 at 4:40 AM
	Lost Money on Summit Therapeutics Inc.(SMMT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation accesswire.com - March 6 at 4:35 AM
	Summit Therapeutics Being Investigated on Behalf of Summit Therapeutics Inc. Investors. Contact Levi & Korsinsky For Details. accesswire.com - March 5 at 3:50 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
April 2, 2024 9:15 AM
View Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
3 Computer Vision Stocks for Long-Term Gains From AI
April 16, 2024 6:08 AM
View 3 Computer Vision Stocks for Long-Term Gains From AI
Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?
April 10, 2024 7:55 AM
View Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?
Intuitive Surgical Leads the Robotic Surgery Movement
April 22, 2024 6:10 AM
View Intuitive Surgical Leads the Robotic Surgery Movement

All Headlines

Company Descriptions

Capricor Therapeutics

NASDAQ:CAPR

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Lumos Pharma

NASDAQ:LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.

Otonomy

NASDAQ:OTIC

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Summit Therapeutics

NASDAQ:SMMT

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial